These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 6452816)

  • 1. Moxalactam for obstetric and gynecologic infections. In vitro and dose-finding studies.
    Cunningham FG; Hemsell DL; DePalma RT; Kappus S; Roark M; Nobles B
    Am J Obstet Gynecol; 1981 Apr; 139(8):915-21. PubMed ID: 6452816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moxalactam therapy for obstetric and gynecologic infections.
    Gall SA; Addison WA; Hill GB
    Rev Infect Dis; 1982; 4 Suppl():S701-7. PubMed ID: 6218587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moxalactam for treatment of pelvic infections after cesarean delivery.
    Cunningham FG; Gibbs RS; Hemsell DL
    Rev Infect Dis; 1982; 4 Suppl():S696-700. PubMed ID: 6218586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moxalactam therapy for bacterial infections.
    Winston DJ; Busuttil RW; Kurtz TO; Young LS
    Arch Intern Med; 1981 Nov; 141(12):1607-12. PubMed ID: 6458253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of cephamycins in obstetrics and gynecology.
    Sweet RL
    J Reprod Med; 1990 Nov; 35(11 Suppl):1064-9. PubMed ID: 2277374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The in vitro activity of moxalactam against 430 clinical, bacterial isolates.
    Digranes A; Benonisen E; Dibb WL; Ostervold B
    Acta Pathol Microbiol Immunol Scand B; 1982 Feb; 90(1):69-72. PubMed ID: 6211028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New drug evaluations: moxalactam (Moxam, Eli Lilly).
    Polk RE
    Drug Intell Clin Pharm; 1982 Feb; 16(2):104-12. PubMed ID: 6210519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of obstetric and gynecologic infections with cefamandole.
    Cunningham FG; Gilstrap LC; Kappus SS
    Am J Obstet Gynecol; 1979 Mar; 133(6):602-10. PubMed ID: 426015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moxalactam in serious infections: clinical, bacteriologic, and pharmacokinetic studies.
    Giamarellou H; Tsagarakis J; Daikos GK
    Rev Infect Dis; 1982; 4 Suppl():S629-38. PubMed ID: 6218576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy of obstetrical infections with moxalactam.
    Gibbs RS; Blanco JD; Castaneda YS; St Clair PJ
    Antimicrob Agents Chemother; 1980 Jun; 17(6):1004-7. PubMed ID: 6447473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Third-generation cephalosporins: a critical evaluation.
    Barriere SL; Flaherty JF
    Clin Pharm; 1984; 3(4):351-73. PubMed ID: 6432420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity, efficacy, and pharmacology of moxalactam, a new beta-lactam antibiotic.
    Snepar R; Poporad G; Romano J; Levison ME
    Antimicrob Agents Chemother; 1981 Nov; 20(5):642-7. PubMed ID: 6459763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of moxalactam against pathogenic bacteria and its comparison with other antibiotics.
    Perrymann F; Flournoy DJ; Qadri SM
    Chemotherapy; 1983; 29(1):37-42. PubMed ID: 6219865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moxalactam in the treatment of pediatric infections.
    Yogev R; Schreiber M; Gardner S; Shulman ST
    Am J Dis Child; 1982 Sep; 136(9):836-9. PubMed ID: 6214182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moxalactam in the treatment of intraabdominal sepsis and other surgical infections.
    Busuttil RW; McGrattan MA; Winston DJ
    Rev Infect Dis; 1982; 4 Suppl():S676-82. PubMed ID: 6218582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience with cefotaxime in obstetric and gynecologic infections.
    Hemsell DL; Cunningham FG; Nolan CM; Miller TT
    Rev Infect Dis; 1982; 4 Suppl():S432-8. PubMed ID: 6294795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefamandole for treatment of obstetrical and gynecological infections.
    Cunningham FG; Gilstrap LC; Kappus SS
    Scand J Infect Dis Suppl; 1980; suppl 25():75-82. PubMed ID: 7010540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Laboratory and clinical studies on latamoxef in the field of obstetrics and gynecology].
    Takase Z; Shirafuji H; Matsuda S; Tanno M; Kashiwakura T; Cho N; Fukunaga K; Kunii K; Hogaki M; Muronosono E; Matsumoto Y; Tabei T; Hayashi S; Nakamura H; Seki K; Fukuda T; Aoyama S; Kurasawa S; Ninomiya K; Hiraoka O; Nakai T; Shimizu H; Sugimoto O; Kamiyoshi S; Watanabe K; Fujimoto A; Doi S; Jujii K; Yamada F; Ozawa M; Shimizu T; Risai T; Morimoto N; Kobayashi H; Kondo I; Saita K; Ibaragi K; Kamigawara Y; Sawaragi I; Yuasa M; Hirabayashi K; Okada E; Shirakawa K; Oniki K; Yamamoto K; Yamabe T; Motomura R; Nakanishi K; Teramoto C; Haraguchi H
    Jpn J Antibiot; 1983 Jan; 36(1):1-15. PubMed ID: 6221127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Experience with lamoxactam in gynecology: application as a monotherapeutic agent in severe genital infections and determination of its concentration in uterine and tubal tissues].
    Petersen EE; Daschner FD; Pelz K; Trennhäuser M
    Geburtshilfe Frauenheilkd; 1982 Dec; 42(12):895-8. PubMed ID: 6219039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of moxalactam against anaerobic bacteria.
    Gilchrist MJ; Washington JA
    Rev Infect Dis; 1982; 4 Suppl():S511-5. PubMed ID: 6218560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.